Therefore, RA can be reasonably concluded to reduce TLR4 expression and activation, thereby decreasing the phosphorylation of its downstream molecules, exhibiting an inhibitory effect on AP1 translocation, reducing inflammation, and alleviating NASH. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatohepatitis.